About Us

WHO WE ARE

PNB Vesper Life Sciences Pvt. Ltd

PNB Vesper Life Sciences Pvt. Ltd is a research-based bio-pharmaceutical organization that is determined to discover drugs for serious diseases and unmet medical conditions. PNB Vesper is currently one of very few companies in India that is focused only on research-based NCEs, rather than generics.

The company based in Kochi, India was incorporated in the year 2011. The company’s promoters have been contracting its preclinical research and development activities with various reputed academic and commercial organizations in the UK, US, Thailand, and India for the last 15 years (even before incorporating PNB Vesper Life Science in 2011).PNB Vesper’s products arise from five programs, cholecystokinin receptor (CCK) program that were under development for more than a decade.

PNB Vesper is actually involved in developing drugs for unmet medical needs. PNB Vesper has synthesized hundreds of molecules and systematically characterized them to select lead molecules. The lead molecules have the potential to treat a variety of diseases including pain, cancer, inflammation such as inflammatory bowel disease (IBD), neurological diseases such as anxiety, depression, metabolic diseases, and others. PNB Vesper’s assets are well protected by intellectual property filings both in the US and many other countries around the World.

The Company currently has 6 (New Chemical Entities) NCE under development, 4 molecules in preclinical phases, 2 molecules in clinical phases.

PNB 001/ GPP-BALACOVIN – CCK2 gastrin antagonist, for the treatment of Inflammatory Bowel Disease (Ulcerative Colitis & Crohn’s Disease), Inflammatory Pain- Dysmenorrhea and COVID 19.
PNB 028- CCK3a or CCK-C isoform-selective antagonist, developed for the treatment of Colon and Pancreatic cancer.
PNB 081- CCK1 or CCK-A antagonist for the treatment of Pancreatitis and Opioid Addiction Disorder
PNB 091- Mixed CCK antagonist for Cocaine Addiction Disorder
PNB 101- CCK3b or CCK C gastrin isoform-selective irreversible antagonist, developed for the treatment of Gastric Cancer and Lung Cancer.
PNB 291- A pan CCK antagonist, is in the late discovery stage for the treatment of CCK + gastrin cancers such as lung, liver and brain cancer.

PNB Vesper is currently functioning as a semi-virtual organization with most of its clinical research, preclinical research, and development activities being conducted by various reputed academic and commercial organizations in the UK, US, Thailand, and India. PNB Vesper’s assets are well protected by intellectual property filings both in the US and many other countries around the World.